This is Tom Lamb's Typepad Profile.
Join Typepad and start following Tom Lamb's activity
Join Now!
Already a member? Sign In
Tom Lamb
Wilmington, NC, USA
Tom Lamb is a lawyer who represents patients and their family in drug injury lawsuits.
Interests: law, news, information, drugs, legal, medical, fda, pharmaceutical, medications, side-effects, drug-injury, drug-safety, regulatory
Recent Activity
Case Reports Of These Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Causing Diabetic Ketoacidosis (DKA) Presented At Recent Medical Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA is investigating a connection between a certain class of diabetes medicines and diabetic ketoacidosis (DKA), ketoacidosis, or ketosis. From "FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood", issued on May 15, 2012: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines [Invokana (canagliflozin), Farxiga (dapagliflozin), and Jardiance (empagliflozin)] may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Patients should pay close attention for any signs of ketoacidosis and seek medical attention immediately if they experience symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness.... A search of the FDA Adverse Event Reporting System (FAERS) database identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA),... Continue reading
Posted 5 days ago at Drug Injury Watch
Quoted from http://www.reuters.com/article/2015/05/15/fda-diabetes-idUSL1N0Y615520150515 UPDATE 2-U.S. FDA warns on newer class of type 2 diabetes drugs By Bill Berkrot May 15, 2015 May 15 (Reuters) - The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The oral drugs belong to a class known as SGLT2 inhibitors that work by causing blood sugar to be secreted in the urine. They include AstraZeneca's Farxiga (dapagliflozin), J&J's... Continue reading
New Medical Research Suggests The Safety Of A Testosterone Drug Might Depend On Its Form: Injections / Shots; Creams / Gels; Skin Patches (Posted by Tom Lamb at DrugInjuryWatch.com) On March 3, 2015 an FDA Drug Safety Communication about testosterone products was issued requiring drug companies to make a “labeling change to inform of possible increased risk of heart attack and stroke with use”. Now, according to a large retrospective cohort medical study published online by the JAMA Internal Medicine journal in May 2015, we learn that short-acting testosterone injections or shots -- such as the Depo-Testosterone (testosterone cypionate) injection from Pharmacia and Upjohn Company (a division of Pfizer) -- are associated with a higher risk of cardiovascular events, hospitalizations, and deaths when compared with gels or patches. From the Abstract for "Comparative Safety of Testosterone Dosage Forms" (an Online First article), we get this overview of the new medical research: Importance Increases in testosterone use and mixed reports of adverse events have raised concerns about the cardiovascular safety of testosterone. Testosterone is available in several delivery mechanisms with varying pharmacokinetics; injections cause spikes in testosterone levels, and transdermal patches and gels cause more subtle but sustained increases. The comparative... Continue reading
Posted May 13, 2015 at Drug Injury Watch
FDA Drug Safety Communication Issued In November 2014 About The Dual Antiplatelet Therapy (DAPT) Trial Which Was Published In The New England Journal of Medicine (Posted by Tom Lamb at DrugInjuryWatch.com) Plavix (clopidogrel) and Effient (prasugrel) are important antiplatelet blood-thinning medicines used to prevent heart attacks, strokes, and other clot-related diseases. The Dual Antiplatelet Therapy (DAPT) trial was published by the New England Journal of Medicine (NEJM) on November 16, 2014 in this article, "Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents". That same day came this related item, "FDA Drug Safety Communication: FDA reviews long-term antiplatelet therapy as preliminary trial data shows benefits but a higher risk of non-cardiovascular death", from which we get this information: FDA is evaluating preliminary data from a clinical trial showing that treatment for 30 months with dual antiplatelet blood-thinning therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment. The clinical trial compared 30 months versus 12 months of treatment with dual antiplatelet therapy consisting of aspirin plus either clopidogrel (Plavix) or prasugrel (Effient), following implantation of drug-eluting coronary stents.... FDA has not... Continue reading
Posted May 6, 2015 at Drug Injury Watch
Quoted from http://www.forbes.com/sites/larryhusten/2015/05/05/200-year-old-heart-drug-linked-to-increased-risk-of-death/ 200-Year-Old Heart Drug Linked To Increased Risk Of Death Larry Husten Forbes May 5, 2015 For more than 200 years physicians have been trying to figure out how and when to use the heart drug digoxin. Although it has a narrow therapeutic window and potentially dangerous interactions with other drugs, it is endorsed by current guidelines and widely given to patients with heart failure (HF) and atrial fibrillation (AF). However, there have been no randomized trials in AF and only one trial, the famous DIG trial, in HF. In that trial digoxin had no impact on mortality... Continue reading
New FDA Rule Requires Drug Company To Replace Current Simple Pregnancy Category Designation With A Summary Of The Risks Of Using Zofran During Pregnancy (Posted by Tom Lamb at DrugInjuryWatch.com) ____________________________ UPDATE: Novartis and GlaxoSmithKline (GSK) have reportedly completed the final stages of GSK’s oncology portfolio buyout. As such, Novartis is now the responsible drug company for Zofran and would be making any Zofran label changes going forward. (5/19/15) _____________________________ Starting earlier this year drug injury products liability lawsuits alleging birth defects caused by the use of Zofran (ondansetron) during pregnancy for so-called "morning sickness" have been filed against the pharmaceutical company GlaxoSmithKline (also known as GSK or Glaxo). One standard contention found in the Zofran lawsuit Complaints filed to date is as follows: GSK falsely and negligently represented to the medical community and expectant mothers, including Plaintiff and her providers, that: a. Zofran was safe and effective for treating pregnancy-related nausea; b. Zofran had been adequately tested and studied in pregnant women; c. Zofran use during pregnancy did not increase the risk of bearing children with birth defects; and, d. Zofran’s “Pregnancy Category B” designation established the safety and efficacy of Zofran for treating pregnancy-related nausea. In December 2014... Continue reading
Posted Apr 29, 2015 at Drug Injury Watch
Muscle-Wasting Side Effect "Rhabdo" Seems To Apply To Entire ADHD Class Of Drugs Given That April 2015 FDA Letter Was Sent To All Manufacturers (Posted by Tom Lamb at DrugInjuryWatch.com) We start in the US where an April 15 FDA letter to drug companies like Janssen Pharmaceuticals (regarding Concerta) stated that new safety information pertaining to the association between the use of stimulants used to treat Attention Deficit Hyperactivity Disorder (ADHD) and rhabdomyolysis, or "rhabdo" for short, should be added to the drug labels for ADHD medications such as these: Adderall Concerta Focalin Ritalin Strattera Vyvanse According to the PubMed Health page for rhabdomyolysis, from the US National Library of Medicine: Rhabdomyolysis is a condition in which damaged skeletal muscle tissue breaks down rapidly. Breakdown products of damaged muscle cells are released into the bloodstream. Some of these, such as the protein myoglobin, are harmful to the kidneys and may lead to kidney failure. Next we turn to an April 2015 Health Canada safety alert about methylphenidate products such as Concerta and Ritalin being associated with prolonged and painful erections -- a medical condition called priapism -- in male patients, including children. From that Health Canada alert about Concerta and... Continue reading
Posted Apr 22, 2015 at Drug Injury Watch
As Analysis Did Not Reveal Causes Of The Increase In Death Incidents, FDA Asks Its Advisory Committee To Discuss This Safety Issue At April 2015 Meeting (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "AstraZeneca, Takeda Diabetes Drugs Should Warn of Risk" (4/15/15, Bloomberg) (4/15/15) ______________________________________________________________________________ The AstraZeneca diabetes drugs Onglyza (saxagliptin) and Kombiglyze (saxagliptin plus metformin) will come under scrutiny at an April 14, 2015 FDA meeting according to early news reports about that upcoming event. We previewed in this April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee in this article we wrote last month, "Cardiovascular Safety Issues For Onglyza And Kombiglyze Will Be Discussed At April 2015 FDA Advisory Committee Meeting". Last Friday, April 10, FDA posted online their Briefing Material document for this Kombiglyze / Onglyza safety meeting (PDF file, 105 pages). _____________________________________________________________________ Free Onglyza / Kombiglyze Case Evaluation Strictly Confidential, No Obligation. ______________________________________________________________________________ As regards what that FDA staff document contained and its significance, from an April 10, 2015 Bloomberg news report, "AstraZeneca’s Diabetes Drug May Raise Death Risk, FDA Says": AstraZeneca Plc’s type 2 diabetes drug Onglyza showed an increased risk of death in an analysis by U.S. regulators of... Continue reading
Posted Apr 13, 2015 at Drug Injury Watch
Quoted from http://www.reuters.com/article/2015/04/10/astrazeneca-onglyza-fda-idUSL2N0X70PU20150410 AstraZeneca's diabetes drug Onglyza may increase death rate - FDA By Toni Clarke April 10 (Reuters) - AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the safety of Onglyza and a similar drug from Takeda Pharmaceutical Co called Nesina. Onglyza won U.S. approval in 2009 and Nesina in 2013. A trial of more... Continue reading
However, It Seems No Further Research About This Congenital Birth Defect Being Caused By Zofran Use During Pregnancy Has Been Done By GlaxoSmithKline (Posted by Tom Lamb at DrugInjuryWatch.com) So-called "morning sickness", or nausea and vomiting (NVP), is the most common medical condition of pregnancy, affecting more the 75% of all pregnancies to some degree. In fact, severe NVP, or hyperemesis gravidarum, can be debilitating and require hospitalization. For many years now, some women with morning sickness have been prescribed Zofran (ondansetron) and had babies born with birth defects and other congenital malformations. Remarkably, Zofran is not even approved by the FDA as a treatment to reduce morning sickness when women are pregnant. Rather, this GlaxoSmithKline drug has been approved by FDA for the prevention of nausea or vomiting associated with chemotherapy and radiotherapy as well as in some instances following surgery. As far back as 2004 some medical researchers have noted that while Zofran is being used for morning sickness, or NVP, there have been no sufficient medical studies examining its safety in pregnancy. From "The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study", published by the medical journal BJOG: an International Journal of... Continue reading
Posted Apr 6, 2015 at Drug Injury Watch
Increased Warning About The Risk Of Suicidal Thoughts And Behaviors Being Added To Attention Deficit Hyperactivity Disorder (ADHD) Drug Labels (Posted by Tom Lamb at DrugInjuryWatch.com) On March 30, 2015 Health Canada issued an Information Update document with new safety information about Adderall, Concerta, Ritalin, and similar medications titled "ADHD drugs may increase risk of suicidal thoughts and behaviors in some people; benefits still outweigh risks". From that item we get this description about the emerging ADHD drugs safety issue: The new warnings advise that there have been reports of suicide-related events in patients treated with ADHD drugs. The reports involved thoughts of suicide, suicide attempts, and in a very small number of cases, completed suicide. These events have been reported at various times during treatment, particularly at the start or during dose changes, and also after stopping the drug treatment.... New information has emerged since to suggest that the risk of suicidal thoughts and behaviours may apply to all other ADHD drugs. There is little evidence to establish that these drugs cause suicidal thoughts and behaviours, but it is possible that they may contribute to the risk.... [emphasis added] The following is a list of some brand name ADHD... Continue reading
Posted Mar 30, 2015 at Drug Injury Watch
Donna: The Pliva, Inc., et al. v. Mensing case was decided by the Supreme Court of the United States (SCOTUS) on June 23, 2011. Justice Clarence Thomas delivered the opinion of the Court, concluding that federal drug regulations applicable to generic drug manufacturers directly conflict with, and thus pre-empt, state law claims. The bottom line is that the US Supreme Court ruled in favor of the generic drug company and against the injured patient such that at the present time any "failure to warn" lawsuit involving a generic drug would be dismissed based on this Mensing case ruling. Justice Sonia Sotomayor, in her dissent opinion, did well in pointing out the apparent absurdity of this new Supreme Court ruling about generic drug company lawsuits: "As a result of today’s decision, whether a consumer harmed by inadequate warnings can obtain relief turns solely on the happenstance of whether her pharmacist filled her prescription with a brand-name or generic drug. The Court gets one thing right: this outcome 'makes little sense'." Certainly not fair to people like you, I agree; but it is the current legal situation in the US as regards genric drugs. Tom Lamb
1 reply
FDA Letters To AstraZeneca And Novo Nordisk Approve Addition Of Information About Increased Risk For Medullary Thyroid Carcinoma (MTC) (Posted by Tom Lamb at DrugInjuryWatch.com) The diabetes drugs Bydureon (exenatide extended-release) for injectable suspension and Victoza (liraglutide [rDNA origin]) injection) were the subject of March 2015 FDA letters concerning the supplemental approval about labeling revisions. Each of these FDA letters, to AstraZeneca and to Novo Nordisk respectively, contain this paragraph: We also refer to our letter dated October 7, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for long-acting GLP-1 receptor agonist products. This information pertains to the risk of medullary thyroid carcinoma. ___________________________________________________________________ Bydureon / Byetta / Januvia / Victoza Free Case Evaluation Strictly Confidential, No Obligation. ___________________________________________________________________________ In both AstraZeneca's Bydureon Prescribing Information and Novo Nordisk's Victoza Prescribing Information, the March 2015 label revisions concerning medullary thyroid carcinoma (MTC) can be seen in the so-called "Black Box" warning at the beginning of that document as well as at part 5.1 Risk of Thyroid C-cell Tumors in the Warnings and Precautions section. As you may know, these diabetes drugs, Bydureon and Victoza, are alleged to... Continue reading
Posted Mar 23, 2015 at Drug Injury Watch
Bayer Claims It Settled About 300 Of These Cases While Another 1300 Lawsuits Were Filed From Mid-October 2014 To The End Of January 2015 (Posted by Tom Lamb at DrugInjuryWatch.com) For establishing a baseline as regards the current progress (or lack thereof) being made by Bayer to resolve the YAZ / Yasmin litigation which began back in 2009, from this article, "December 2014 YAZ / Yasmin Litigation Update: Still Over 2000 DVT And/Or PE Cases Not Settled According To Bayer's Most Recent Financial Report", we get these numbers: As of October 13, 2014, the number of claimants in the pending lawsuits and claims in the United States totaled about 4,000 (excluding claims already settled). As of October 13, 2014, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 9,200 claimants in the U.S. for a total amount of about US$1.8 billion. Next, we go to the PRODUCT-RELATED LITIGATION part of Bayer's Annual Report 2014 (at pg. 311 of the PDF document): Yasmin™ / yaz™: As of January 31, 2015, the number of claimants in the pending lawsuits and claims in the United States totaled about 5,000 (excluding claims already settled). Claimants allege that they have... Continue reading
Posted Mar 16, 2015 at Drug Injury Watch
Quoted from http://www.reuters.com/article/2015/03/09/us-pfizer-chantix-warning-idUSKBN0M527T20150309 U.S. FDA warns of seizure, alcohol risk with Pfizer's Chantix Mon Mar 9, 2015 (Reuters) - The U.S. Food and Drug Administration warned on Monday that Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. The agency said it approved an update to the drug's label in September but issued the public notice to ensure patients are aware of the changes "and can consider this new information when making prescribing decisions." Typically such warnings are made at the time of... Continue reading
These Two New AstraZeneca Diabetes Medications With Saxagliptin Are Part Of The Incretin Mimetic Class Of Drugs (Posted by Tom Lamb at DrugInjuryWatch.com) At an April 14, 2015 meeting of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, results of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial for for AstraZeneca's relatively new diabetes drugs Onglyza (saxagliptin) and Kombiglyze XR (saxagliptin and metformin HCI extended-release) will be discussed. For some background, one might want to read this article, "Possible Link Between Heart Failure And Onglyza Diabetes Type 2 Drug Is Being Investigated By FDA, As Announced In February 2014", which we posted about a year ago. From a March 2015 statement issued by AstraZeneca in connection with this upcoming Kombiglyze XR / Onglyza FDA Advisory Committee Meeting: The SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza (saxagliptin) was a randomised, double-blind, controlled trial evaluating the effect of saxagliptin on the incidence of major adverse cardiovascular events in patients with type 2 diabetes mellitus and at an elevated risk for CV events. The SAVOR study was conducted as part of the Postmarketing Requirement for the US New... Continue reading
Posted Mar 9, 2015 at Drug Injury Watch
Quoted from http://www.reuters.com/article/2015/03/03/us-usa-health-testosterone-idUSKBN0LZ2NE20150303 FDA limits use of testosterone drugs, warns of possible heart risk Tue Mar 3, 2015 (Reuters) - The U.S. Food and Drug Administration has asked makers of prescription testosterone therapies to change their labeling to clarify that their products are approved only for men with specific medical conditions and could increase the risk of heart attacks and strokes. Prescriptions for low testosterone, or "Low T" have soared over the past decade, driven by a surge in use by men facing falling testosterone levels as they age. The number of men being prescribed testosterone jumped more than 75... Continue reading
With New Jersey State Court Fosamax Lawsuits Now Assigned To Judge Mayer, We Hope These Cases Get Back On Track (Posted by Tom Lamb at DrugInjuryWatch.com) In our last update, "December 2014 Fosamax - Femur Fracture Litigation Update: In The Fosamax Federal Court MDL There Are Dismissals, Appeals, And Court-Ordered Mediations", we only mentioned in passing the New Jersey state court Fosamax femur fracture litigation. Even though there is little new information about those cases, this is where we begin in our first Fosamax update for 2015. From Merck's Form 10-K Annual Report For the Fiscal Year Ended December 31, 2014 we get this information about the femur fracture aspect of the Fosamax products liability litigation (at pp. 110-111 of the PDF document): As of December 31, 2014, approximately 3,005 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge Jessica Mayer in Middlesex County. The parties selected an initial group of 30 cases to be reviewed through fact discovery. Two additional groups of 50 cases each to be reviewed through fact discovery were selected in November 2013 and March 2014, respectively. The current number of these Fosamax lawsuits means there were about... Continue reading
Posted Mar 2, 2015 at Drug Injury Watch
Thank you for your Comment. Please understand, however, that because I am not a physician but only an attorney I am not in a position to give any medical opinion as regards your situation. Perhaps some other qualified person could provide you with some medical guidance. I wish you the best in all aspects going forward. Tom Lamb
1 reply
Quoted from http://www.philly.com/philly/business/20150225_Johnson___Johnson_loses_first_Risperdal _jury_trial.html Johnson & Johnson loses first Risperdal jury trial Posted: Wednesday, February 25, 2015, 1:08 AM A Philadelphia jury said Tuesday that drugmaker Johnson & Johnson should pay $2.5 million to a 20-year-old autistic man from Alabama - who developed size 46 DD breasts as a young teenager - because the company failed to adequately warn of that potential side effect from his use of the antipsychotic drug Risperdal. This was the first case related to the condition called gynecomastia that went to a jury, but thousands more lawsuits are lined up in Philadelphia, California, Missouri, and... Continue reading
Company Is Investigating This Gilenya - PML Case To See Whether Brain Disease Might Be A Side Effect Of Its MS Drug (Posted by Tom Lamb at DrugInjuryWatch.com) Gilenya (fingolimod) capsules were approved by the FDA in 2010 and by Health Canada in 2011. We posted this article about Gilenya last week, on February 16, "Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis (MS) Medication Gilenya". In that article we looked at the cardiac-related risks associated with Gilenya. A few days later we saw this news report on the website for the Multiple Sclerosis Society of Canada, "Case of PML reported in patient treated with Gilenya®", and from from that article we get this more recent drug safety information: Pharmaceutical company Novartis has reported a case of PML (progressive multifocal leukoencephalopathy) in an individual who had received Gilenya® (fingolimod) for more than 4 years for the treatment of relapsing-remitting multiple sclerosis (RRMS). Novartis has informed the regulatory authorities of this case, and is investigating whether treatment with Gilenya® contributed to the development of PML.... This is the third case of PML observed for Gilenya®. The first case was reported in 2012, wherein Novartis had noted that... Continue reading
Posted Feb 23, 2015 at Drug Injury Watch
Quoted from http://health.usnews.com/health-news/articles/2015/02/16/study-links-antibiotics-to-digestive-complication-in-infants Study Links Antibiotics to Digestive Complication in Infants HealthDay Feb. 16, 2015 By Tara Haelle HealthDay Reporter MONDAY, Feb. 16, 2015 (HealthDay News) -- Using certain antibiotics early in infancy may raise the risk of a serious gastrointestinal condition called pyloric stenosis, a new study indicates. Doctors have known that using the antibiotic erythromycin can increase the risk of pyloric stenosis in infants. The new findings confirmed that link, and also found that the antibiotic azithromycin (Zithromax) is associated with a higher risk of pyloric stenosis when given to infants under 6 weeks old. "Ingestion of oral... Continue reading
ISMP QuarterWatch Report From 2014 States Adverse Events Reports Show That Gilenya Cardiac Risks "were neither rare nor hypothetical" (Posted by Tom Lamb at DrugInjuryWatch.com) The safety profile for the Novartis drug Gilenya (fingolimod) has been controversial for some time now, and the concerns about adverse reactions and side effects continue. As background, in August 2012 we posted this article, "Multiple Sclerosis (MS) Medication Gilenya: Timeline Of Actions Taken In US, Canada, And Europe". And over the past several years we have been monitoring news reports about Gilenya adverse reactions and suspected side effects at our Pharmaceutical Drug Litigations Updates site. Last fall, from the September 24, 2014 edition of the ISMP QuarterWatch publication, we received more data and information about the various safety risks associated with Gilenya. We start with this overview from "Update on Fingolimod (GILENYA)" in the Executive Summary section: ... three years of postmarket and new published data highlight four important safety risks of [Gilenya (fingolimod)].... Adverse event reports for the most recent 12 months showed the cardiac risks were neither rare nor hypothetical.... Also identified was a large group of cases (n = 348) indicating macular degeneration or less specific adverse effects on the eye.... Continue reading
Posted Feb 16, 2015 at Drug Injury Watch
Medical Researchers Find Increased Risk Of Heart Defects And Cleft Palates In Babies Born To Women Using Zofran (Posted by Tom Lamb at DrugInjuryWatch.com) Women with severe morning sickness who were prescribed Zofran (ondansetron) -- a GlaxoSmithKline drug approved by FDA for the prevention of nausea and vomiting associated with chemotherapy and radiotherapy -- have had babies born with heart-related birth defects and other congenital malformations such as cleft palate and/or cleft lip. For some background facts regarding this emerging drug-safety issue we begin with a June 2014 investigative news report, "Birth defects blamed on unapproved morning sickness treatment", which was published by the Toronto Star newspaper. Here are three important points taken from that article: [#1] Because most women experience nausea and vomiting during the first trimester, they would be taking the drug at the same time the fetus is most vulnerable to developing malformations and deformities. Roughly 10 to 15 per cent of pregnant women receive drugs to treat morning sickness, according to a recent U.S. study. ********** [#2] In 2012, the U.S. Department of Justice reached a $3-billion settlement with GlaxoSmithKline after the government alleged the company promoted the off-label uses of several drugs, including Zofran, the... Continue reading
Posted Feb 9, 2015 at Drug Injury Watch
Researchers Surprised By Their Finding As Earlier Medical Studies Suggested Anticancer Effect In Prostate (Posted by Tom Lamb at DrugInjuryWatch.com) Findings about increased cancer risks being associated with the use of erectile dysfunction (ED) drugs such as Viagra, Cialis, and Levitra are not new, as those relatively popular drugs and others had been associated with melanoma. For more about that drug side effect see our Viagra / Cialis / Levitra / Staxyn / Stendra / Revatio / Adcirca drug information page. The February 2015 edition of The Journal of Urology includes this article, "Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy", which was published online back in September 2014. From the Abstract for this recent medical journal article about Viagra, Cialis, and Levitra: Purpose Experimental evidence suggests that phosphodiesterase type 5 inhibitors may suppress tumor growth, postpone metastasis and prolong survival, but clinical data are lacking. We studied the effect of phosphodiesterase type 5 inhibitors on biochemical recurrence after radical prostatectomy for prostate cancer. Conclusions Contrary to experimental data, the use of phosphodiesterase type 5 inhibitors after radical prostatectomy may adversely impact biochemical recurrence. Further studies are needed to validate our results. _____________________________________________________________________ Viagra... Continue reading
Posted Feb 2, 2015 at Drug Injury Watch